aIM: Cushing's disease (CD) is caused by ACTH-secreting pituitary adenoma. Transsphenoidal surgery (TSS) is the treatment of choice. CD diagnosis must be based on biochemical confirmation of hypercortisolemia and visualization of pituitary tumor on magnetic resonance imaging (MRI). Diagnostic problems are associated with equivocal or even normal MRI. In such situations, some neurosurgical centers perform a diagnostic sellar exploration. The purpose of this study was to evaluate the relationship between the results of preoperative MRI of the pituitary and efficacy of TSS for CD.
BACkgRound
The hallmark of Cushing' s disease is chronic hypercortisolemia caused by excessive, autonomous secretion of corticotrophin (ACTH) by the pituitary adenoma (1, 15) . Despite the relatively low incidence (estimated at 1 -3 new cases per million inhabitants per year), the disease constitutes one of the greatest challenges of modern endocrinology and neurosurgery (11, 13) . Once ACTH-dependent hypercortisolemia is biochemically confirmed, it becomes necessary to perform optimal neuroradiological procedures, aimed at obtaining the most precise visualization of suspicious focal lesion within the pituitary gland.
According to the generally adopted criteria, the magnetic resonance imaging (MRI) is the visualization method of choice in diagnostics of Cushing' s disease (7, 14, 15) . Due to the fact that pituitary microadenomas are responsible for more than 80% of all cases of ACTH -dependent Cushing' s syndrome of pituitary origin, the most frequently observed MR image ( Figure 1A ) displays the focal lesion with the diameter of less than 10 mm, usually hypodense after intravenous contrast (15) . Furthermore the corticotroph pituitary microadenomas do not exceed the diameter of 5 mm even in as much as 50% of cases. This constitutes the fundamental difficulty in neuroradiological imaging of pituitary corticotrophic adenomas and sometimes makes it necessary to search for indirect features of the presence of pituitary adenoma, such as deviation of the pituitary stalk ( Figure 1B ) or convex upper surface of the pituitary gland.
The issues presented above clearly make further surgical treatment more difficult to perform. Sometimes they force a neurosurgeon to make an attempt of intraoperative localization of a focal lesion within the pituitary gland. Furthermore, rarely occurring corticotroph pituitary macroadenomas, due to their size and ability to infiltrate surrounding structures ( Figure 1C, D) , constitute a real challenge for a neurosurgeon, forcing the physician to make technically difficult and risky attempts to relieve compression of the optic chiasm, internal carotid arteries or cavernous sinuses (9, 10, 17) .
Considering the above, it seems that precise, preoperative MR imaging as well as proper interpretation of obtained results may contribute to optimize the principles of diagnostic and therapeutic procedures used in the treatment of this relatively rare but severe and devastating disease. Therefore, the purpose of this study was to prospectively evaluate the importance of preoperative MRI findings for the efficacy of neurosurgical treatment of Cushing' s disease. 
Clinical course of the disease and preoperative endocrine evaluation
The diagnosis of ACTH -dependent Cushing' s syndrome (CS) was made based on the clinical signs and standard hormonal criteria: increased urinary excretion of urinary free cortisol (UFC), the loss of cortisol circadian rhythm (serum cortisol level above 7.5µg/dl in the late-night hours), increased or detectable level of plasma ACTH at 8.00 and the failure of serum cortisol to suppress to less or equal than 1.8μg/dl during the low dose dexamethasone suppression test (LDDST; 0.5mg q.i.d. for 48 hours). The pituitary aetiology of CS was confirmed based on a serum cortisol and UFC suppression greater than 50% on high dose dexamethasone suppression test (HDDST; 2mg q.i.d. for 48h) and positive MRI. In case of equivocal results of hormonal assessment and pituitary imaging the diagnosis of Cushing`s disease was confirmed by a positive result of stimulation test with intravenous CRH injection (100 μg).
Preoperative MR imaging
All patients underwent high resolution magnetic resonance imaging of the pituitary -hypothalamic region (SIEMENS Symphony 2004; 1.5 Tesla). The MRI scans were performed before and after intravenous injection of Gadolinium (Gd-DTPA). The presence, size and position of any focal lesion was recorded. It was determined that the presence of a hypodense lesion after contrast indicates the pituitary adenoma. Microadenoma was defined as a pituitary tumor with a diameter of less than 1 cm on any dimension whereas macroadenoma -with a size of at least one diameter more than 1 cm. The MRI was qualified as equivocal if the pituitary tumor was not precisely visualized or only the indirect traits of the tumor were present such as the deviation of the pituitary stalk or a convex upper surface of the pituitary gland.
Surgical procedure
A microsurgical transseptal transsphenoidal approach was used for resection of an ACTH-secreting pituitary adenoma. The sella was exposed and an H-shaped incision of the dura was made. Then the gland was carefully explored, regardless of MRI findings. Selective adenomectomy was performed in all cases of precisely visualized focal lesion on MR imaging. When the MR was equivocal or no tumor was evident, a series of vertical and horizontal incisions of the pituitary gland was carried out and all tissue deemed to be abnormal was removed and submitted for pathological examination. Hemihypophysectomy (compared to the corresponding site showing the MRI abnormality), subtotal hypophysectomy, or total hypophysectomy was performed for patients where no abnormal tissue could be identified intraoperatively.
Histopathological and immunohistochemical assessment
The surgical specimen was collected for histopathological analysis and routinely stained with hematoxylin and eosin. Immunohistochemical staining for pituitary hormones was performed according to the labelled EnVision Flex Visualization System (DAKO K8000). The result of histopathological analysis was considered "positive" if the presence of adenoma as well as the immunopositivity for ACTH was confirmed. The result was treated as "negative" if there was no histopathological evidence of the corticotrophic adenoma and ACTH-staining was negative.
Postoperative hormonal evaluation and criteria of cure
Blood samples for serum cortisol measurements were collected from all patients at 6.00 on the first postoperative day. Hydrocortisone replacement therapy was started after biochemical confirmation of hypocortisolemia or in case of the development of clinical symptoms of adrenal insufficiency. During the first two postoperative days the hydrocortisone was given intravenously in a daily dose 50 mg t.i.d. Afterwards the standard dose of hydrocortisone (20 mg in the morning and 10 mg at 15.00) was started and continued until the next hormonal evaluation. Following the surgical procedure all patients were subjected to further postoperative evaluation lasting at least 18 months (median 30 months; range 18 -36 months).
The patients were regarded as cured if they fulfilled the following criteria for remission: subnormal serum cortisol on the 1 st postoperative day and (at the end of follow-up): clinical and biochemical evidence of eucortisolemia (morning serum cortisol between 5 -25 μg/dl), the normal circadian rhythm (the late night serum cortisol level ≤ 7.5 μg/dl) and the ability of serum cortisol to suppress to less or equal than 1.8 μg/dl following the overnight 1 mg dexamethasone suppression test.
Hormone assay

Chemiluminescent immunometric assays (IMMULITE 2000;
Siemens, Great Britain) were used to measure serum and urinary cortisol. Method sensitivity was 0.2 μg/dl (5.5 nmol/l). The normal range for cortisol is 5 -25 μg/dl (138 -690 nmol/l) whereas for UFC -20 -90 μg/24h. Plasma ACTH was measured using a specific twostep radioimmunometric assay (IRMA). The method sensitivity was 1.2 pg/ml and the referral range: 10 -60 pg/ml.
Statistical analysis
Methods of descriptive statistics (mean, median, standard deviations) were employed. Verification of hypotheses concerning the relationship between two categorical variables was expressed as frequencies and compared using the exact chisquare test (Fisher's exact test). In the study by Fomekong et al. the efficacy of operative treatment in the subgroup of micro-and macroadenomas was similar (84% vs. 92%, lack of statistical significance) and significantly greater than in the subgroup with noncharacteristic MR image, in which not a single patient was cured (8) . This puzzlingly high frequency of Cushing's disease remission in patients with pituitary macroadenoma is probably associated with the fact that the authors did not have material with large invasive corticotroph tumors infiltrating adjacent structures. The mean, maximum size of pituitary macroadenoma reported in this study was 1.5 cm and the largest lesion was 2.5 cm in diameter. The results prove that the division of corticotropic tumors into microadenomas and macroadenomas based on the criterion of largest tumor size of ≥ 1 cm is only conventional in nature. It seems that macroadenomas of "intermediate" sizes between 1-1.5 cm, which are easily seen and do not infiltrate the surrounding structures may be relatively easier for an operator to completely remove, which is why efficacy of operative
ReSulTS
The pituitary microadenoma was confirmed in 22 patients (61.1%) whereas macroadenoma was found in 6 patients (16.7%). The equivocal results of MR imaging was observed in 8 patients with Cushing's disease (22.2%).
With reference to a group of 8 patients with equivocal MR results it was assumed that in their case ACTH-dependent Cushing`s syndrome was caused by a very small (1-3 mm) in diameter pituitary microadenomas. Such small focal lesions remains outside the range of detection of even the most sensitive neuroradiological imaging methods. Therefore, being aware that in diagnostics of Cushing`s disease the MRI results should be considered alongside with biochemical results, after confirmed diagnosis of Cushing`s disease in hormonal evaluations, the patients were referred to the Department of Neurosurgery to consider undergoing the diagnostic sellar exploration.
Based on hormonal evaluation carried out on the 1st postoperative day and at the end of 18 months follow-up, 17 of 22 patients (77.3%) with pituitary microadenoma precisely visualized in MRI were regarded as cured. In the subgroup of patients with macroadenoma the surgical treatment efficacy was lower -only 3 of 6 patients (50%) were surgically cured. The lowest treatment efficacy was observed in the subgroup of patients with equivocal MRI results -the sustained remission was confirmed only in 3 of 8 patients (38.5%).
Furthermore we verified the relationship between the surgical cure from Cushing's disease and results of preoperative tumor imaging. To achieve this, we compared a subgroup of patients with the "beneficial" feature, understood as precisely visualized pituitary microadenoma in MR examination with a subgroup of patients with an "adverse" feature. The latter included patients with pituitary macroadenoma as well as patients with equivocal MRI findings. Both "adverse" features were investigated together only due to the relatively small number of studied patients. In the Fisher`s test the statistically significant difference was demonstrated between the cured and uncured subgroups with reference to preoperative MR imaging result (p=0,036) ( Table I) . 
ConCluSIonS
The results of our prospective study indicate that precise visualization of a microadenoma in preoperative MR imaging of the pituitary may be regarded as one of beneficial prognostic factors increasing the probability of achieving surgical cure of Cushing's disease. On the other hand, presence of pituitary macroadenoma or equivocal results of preoperative MRI are related to decreased efficacy of surgical treatment.
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